Anticoagulation/Thromboembolism
RSSArticles
-
Value of ECG LVH in Aortic Stenosis
Progressive, compensatory left ventricular hypertrophy (LVH) in aortic stenosis (AS) ultimately leads to myocardial injury, fibrosis, and LV dysfunction. -
Thienopyridine Pretreatment in Patients with Non-ST Elevation Acute Coronary Syndromes: Where’s the Evidence?
In their recent meta-analysis, Bellemain-Appaix and colleagues looked at thienopyridine (P2Y12 inhibitor) pretreatment in seven studies that included primarily NSTEACS patients, including four randomized, controlled trials and three registries. In the overall cohort, pretreatment did not reduce the risk of all-cause mortality or cardiovascular death. Major adverse cardiovascular events were reduced in the pretreatment group (odds ratio [OR], 0.84; 95% confidence interval [CI] 0.72 to 0.98; P = 0.02), but individual endpoints, such as myocardial infarction, were not significantly affected. Among the subset of patients who underwent percutaneous coronary intervention (PCI), which represented a minority of the total cohort, there was likewise no reduction in death or cardiovascular death, but pretreatment with P2Y12 inhibitors was associated only with a non-significant trend toward a reduction of major adverse cardiac events (MACE). Within the PCI group, pretreatment was associated with a reduction of urgent revascularization (OR, 0.72; 95% CI, 0.52 to 1.00); however, this result was driven primarily by the results of the PCI subset of the CURE, in which the delay from admission to revascularization averaged a relatively long 10 days.
-
Pharmacology Watch: GlaxoSmithKline Withdraws Lymerix: Company ‘Cuts Losses’ on Controversial Lyme Disease Vaccine
-
Cardiac monitor may aid critical burn patients
-
Improve care of patients with new cardiac drug
-
Is Less More? Transfemoral TAVR: The Minimalist Approach
Since its initial FDA approval in November 2011, transcatheter aortic valve replacement (TAVR) has rapidly gained acceptance as a standard therapy in the United States. -
Is Left Atrial Appendage Occlusion with the Watchman Device a Reasonable Alternative to Anticoagulation with Warfarin?
The goal of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial was to assess the safety and efficacy of left atrial appendage (LAA) occlusion for stroke prevention in patients with atrial fibrillation (AF) compared with long-term warfarin therapy -
Bioabsorbable Coronary Scaffolds: Promise and Peril
Clinical outcomes from percutaneous coronary intervention (PCI) have steadily improved over time, with transitions from balloon angioplasty to bare-metal stenting, and more recently from first-generation drug-eluting stents (DES) to second- and third-generation designs. -
Colchicine for Recurrent Pericarditis
Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences. Thus, Imazio et al reported on the results of the colchicine for recurrent pericarditis 2 (CORP-2) trial. -
Pharmacology Watch and Clinical Briefs in Primary Care Available Online
The September 2014 issues of Pharmacology Watch and Clinical Briefs in Primary Care are now available exclusively by e-mail or online.